Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 66Lymphoma, Follicular 21Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Mantle-Cell 10Lymphoma 10Recurrence 7Lymphoma, B-Cell, Marginal Zone 7Neoplasms, Plasma Cell 6Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Smoldering Multiple Myeloma 3Neoplasms 3Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Plasma Cell 2Leukemia, Myelomonocytic, Chronic 2Hematologic Diseases 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1

Interventions

daratumumab 4Lenalidomide 3dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Dexamethasone 2Curcumin 2Calcium Dobesilate 2piperine 1isatuximab 1iberdomide 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Leflunomide 1IPH-2101 1Dietary Fiber 1Diet, Mediterranean 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Lenalidomide × 90 days × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡